SHR8008 + Fluconazole
Phase 3UNKNOWN 2 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Vulvovaginal Candidiasis
Conditions
Recurrent Vulvovaginal Candidiasis
Trial Timeline
Sep 14, 2021 → Sep 30, 2023
NCT ID
NCT05074602About SHR8008 + Fluconazole
SHR8008 + Fluconazole is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Recurrent Vulvovaginal Candidiasis. The current trial status is unknown. This product is registered under clinical trial identifier NCT05074602. Target conditions include Recurrent Vulvovaginal Candidiasis.
What happened to similar drugs?
6 of 20 similar drugs in Recurrent Vulvovaginal Candidiasis were approved
Approved (6) Terminated (0) Active (14)
Hype Score Breakdown
Clinical
17
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05074602 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Recurrent Vulvovaginal Candidiasis